2022 Fiscal Year Final Research Report
Can the tumor metabolic reprogramming be a novel therapeutic means for malignant meninigomas ?
| Project/Area Number |
20K17943
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56010:Neurosurgery-related
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 髄膜腫 / 不均一性 / 病理組織学的悪性度 / 分子生物学的悪性度 / メタボローム解析 / トランスクリプトーム解析 |
|---|
| Outline of Final Research Achievements |
In this study, we performed metabolome and transcriptome analyses for meningothelial, atypical and anaplastic meningiomas. As a result of our research, WHO grade 2 (G2) meningioma included a molecular-biologically different subgroup (G2m group). G2m group were similar to WHO grade 1, meningothelial meningioma in the metabolites and the gene expression. They, however, had an upregulated change in metabolic pathway like a malignant tumor, which was so-called glutaminolysis. Finally, we proved the hypothesis that the metabolic pathway could change along with malignant change in meningiomas.
|
| Free Research Field |
脳腫瘍学
|
| Academic Significance and Societal Importance of the Research Achievements |
これまでにも、異型性髄膜腫には臨床的に再発が認められない予後良好群と、容易に再発する予後不良群が混在していると考えられてきたが、本研究の結果、分子生物学の側面から悪性度の異なる亜群が存在することを証明した意義は大きい。これは、異型性髄膜腫が髄膜腫の悪性化の分子機序を解明する鍵となりうる可能性を示唆している。、また、この亜群では特徴的な代謝経路の変動も同定されており、この代謝経路の変動を制御することで難治性の悪性髄膜腫に対する新たな治療ターゲットが見出せる可能性もある。
|
